Pathogenicity and Full Genome Sequencing of the Avian Influenza H9N2 Moroccan Isolate 2016.

In Morocco in early 2016, a low pathogenic avian influenza virus serotype H9N2 caused large economic losses to the poultry industry, with specific clinical symptoms and high mortality rates on infected farms. Subsequent to the H9N2 outbreak, the causal agent was successfully isolated from chicken flocks with high morbidity and mortality rates, propagated on embryonated eggs, and fully sequenced. The phylogenetic analysis suggested that the Moroccan isolate could have derived from the Middle East isolate A/chicken/Dubai/D2506.A/2015. This study was designed to assess the pathogenicity of the Moroccan isolate H9N2 in experimentally infected broiler and specific-pathogen-free (SPF) chickens. At 22 days of age, one broiler and two SPF chicken groups were inoculated by dropping 0.2 ml of the H9N2 isolate (107.5 EID50/ml) in both nostrils and eyes. Clinically inoculated chickens with H9N2 displayed mild lesions, low mortality rates, and an absence of clinical signs. The H9N2 virus was more pathogenic in broiler chickens and produced more severe tissue lesions compared to SPF chickens. The viral shedding was detected up to 6 days postinoculation (pi) in oropharyngeal and cloacal swabs in infected birds with a maximum shedding in the oropharynges of the broiler group. All experimental chickens seroconverted and registered high hemagglutination inhibition titers as early as day 7 pi. The present study indicates that the H9N2 virus isolated from a natural outbreak was of low pathogenicity under experimental conditions. However, under field conditions infection with other pathogens might have aggravated the disease.

Estudio de patogenicidad y secuenciación del genoma completo del aislamiento de virus de la influenza aviar H9N2 de Marruecos del año 2016. En Marruecos, a principios de año 2016, el serotipo H9N2 del virus de la influenza aviar de baja patogenicidad (LPAIV) causó grandes pérdidas económicas en la industria avícola, con signos clínicos específicos y altas tasas de mortalidad en las granjas infectadas. Posterior al brote de H9N2, el agente causal se aisló con éxito de parvadas de pollos con altas tasas de morbilidad y mortalidad, se propagó en huevos embrionados y se secuenció completamente. El análisis filogenético sugirió que el aislado marroquí podría haberse derivado del aislamiento de Medio Oriente (A/pollo/Dubai/D2506.A/2015). Este estudio se diseñó para evaluar la patogenicidad del aislado marroquí H9N2 en pollos de engorde infectados experimentalmente y en pollos libres de patógenos específicos (SPF). A los 22 días de edad, un grupo de pollos de engorde y dos grupos de aves libres de patógenos específicos se inocularon mediante la instilación de 0.2 ml del aislamiento H9N2 (107.5 dosis infectantes de embrión de pollo 50% [EID50] por ml) en ambas fosas nasales y en los ojos. Los pollos clínicamente inoculados con el virus subtipo H9N2 mostraron lesiones leves, bajas tasas de mortalidad y ausencia de signos clínicos. El virus H9N2 fue más patógeno en los pollos de engorde y produjo lesiones tisulares más graves en comparación con las aves libres de patógenos específicos. La excreción viral se detectó hasta seis días después de la inoculación en frotis orofaríngeos y cloacales de aves infectadas con una excreción máxima en la orofarínge del grupo de pollos de engorde. Todos los pollos experimentales seroconvirtieron y registraron altos títulos de inhibición de hemaglutinación tan pronto como en el día siete después de la inoculación. El presente estudio indicó que el aislamiento viral H9N2 de un brote natural fue de baja patogenicidad en condiciones experimentales. Sin embargo, en condiciones de campo, la infección con otros patógenos pudo haber agravado la enfermedad.

Preliminary results on innocuity and immunogenicity of an inactivated vaccine against Peste des petits ruminants.

Peste des petits ruminants (PPR) virus belongs to the family Paramyxoviridae and represents a major threat to small livestock industry. In recent years, outbreaks of PPR have occurred in Turkey and North Africa. In endemic areas, disease prevention is accomplished using live­attenuated vaccines. However, the use of live vaccines in non­endemic regions, such as Europe, is not approved by Veterinary Authorities. In these regions inactivated vaccines are then the only viable alternative. In this study an inactivated vaccine (iPPRVac) was formulated with either a water­in­oil emulsion (ISA 71 VG) or with delta inulin adjuvant, alone (AFSA1) or combined with a TLR9 agonist oligonucleotide (AFSA2). These formulations were then tested for immunogenicity on rats. The iPPRV formulation with AFSA2 adjuvant induced 100% seroconversion in rats after 2 injections and was subsequently evaluated in goats. Five goats were immunised twice subcutaneously, 36 days apart with iPPRVac + AFSA2. The immunised goats all seroconverted to PPR by day 9 and remained seropositive until the end of the experimental period (133 days). These data indicate that the rat model is useful in predicting vaccine responses in goats and that inactivated vaccine, when formulated with a delta inulin adjuvant, represents a promising alternative to live attenuated vaccines for PPR vaccination campaigns in non­endemic areas.